New immunotherapy drugs offer some hope in the fight against Alzheimer's disease but they're too pricey for the NHS ...

Donanemab, developed by the pharmaceutical company Lilly, is given to patients via an intravenous drip once every four weeks. Lecanemab, developed by Eisai, is also given this way, but fortnightly.

After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

Donanemab, developed by the pharmaceutical company Lilly, is given to patients via an intravenous drip once every four weeks. Lecanemab, developed by Eisai, is also given this way but fortnightly.

After a lifetime of good fortune, the generation has become vulnerable at exactly the wrong moment.

The New York Times ran a lengthy interview this morning between columnist Ross Douthat and venture capitalist and PayPal ...

What exactly is Alzheimer’s disease, and how common is it? A: Alzheimer’s disease is a neurodegenerative disease that causes dementia. It is caused in part by the accumulation of abnormally folded ...

Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional cost to the NHS The benefits from donanemab (also called Kisunla and made by Eli Lilly) and ...

Pharmaceutical firm Lilly, maker of donanemab, said it will appeal the decision. It slammed: “If the system can’t deliver scientific firsts to NHS patients then it is broken.” ...

Alzheimer’s drugs, Donanemab and Lecanemab, have been rejected for the NHS due to the benefits being ‘too small’ to justify the cost, as ITV News' Aisha Zahid reports ...

Alzheimer’s drugs rejected for NHS because benefits ‘too small’ to justify cost Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s.

Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to suggest ...